Navigation Links
MEDICAGO ANNOUNCES 2010 THIRD QUARTER FINANCIAL RESULTS
Date:11/12/2010

Status of Phase II H5N1 clinical trial Enrollment is ongoing and vaccination has commenced in the Company's phase II clinical trial with its H5N1 pandemc influenza vaccine. Interim results from this study are expected within three months. Financial Results Consolidated loss for the three-month period ended September 30, 2010 was $4,104,000 or $0.03 per basic and diluted share compared to a loss of $3,165,000 or $0.03 per basic and diluted share for the three-month period ended September 30, 2009.  Since the beginning of the year the consolidated loss was $11,766,000 or $0.09 per basic and diluted share compared to a loss of $8,584,00 or $0.09 per basic and diluted share. Increase in the loss for the three and nine-month period is explained by the increase in R&D expenses in relation with the Phase II clinical trials that is underway.

Cash and cash equivalents were $14.7 million as at September 30, 2010.

As at November 12, 2010, there were 136,912,102 common shares issued and outstanding, 7,344,047 stock options outstanding, 3,796,982 unit options outstanding and 26,209,586 warrants outstanding.

Detailed financial statements and the MD&A are available at www.medicago.com or www.sedar.com. Grant of stock options Pursuant to terms and conditions of Medicago Inc.'s stock option plan, the company has granted 239,000 stock options to employees. The stock options were issued at an exercise price of 0.40 cents, will vest in three yearly instalments and are set to expire 10 years from the date of the grant. About Medicago Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against pandemic and seasonal influenza using a transient expression system which produces recombinant vaccine antigens in non-tr
'/>"/>

SOURCE Medicago Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Medicago initiates work on Swine Flu strain
2. Medicago succesfully expresses VLP antigen for A H1N1 strain
3. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
4. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
5. Medicago begins human clinical testing with its avian flu pandemic vaccine
6. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
7. Medicago to present at the U.S. Department of Health and Human Services Global Health Security Initiative Workshop
8. Medicago reports positive Phase I results for its avian flu pandemic vaccine
9. Medicago named in Presidential report on meeting the challenges of pandemic influenza
10. Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications
11. Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... NEW YORK , Aug. ... announces that a new market ... its catalogue: Whole ... (Systems, Kits (Library Preparation, Target ... Technology (Sequencing by Synthesis), by ...
(Date:8/28/2014)... 28, 2014  Armetheon, Inc. ( www.armetheon.com ), ... to late-stage cardiovascular drug candidates, today announced that ... round of financing. The Series A round was ... with participation from investors that included Atheneos Capital ... Larry Hsu , the founder of Impax ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a ... SoundConnect to support their communication needs with ... web conferencing platform GlobalMeet powered by SoundConnect. The ... SoundConnect delivers award winning “results driven” business ... will be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/27/2014)... BOSTON , Aug. 27, 2014 Rhythm, ... diseases and genetic deficiencies that result in metabolic disorders, ... on Form S-1 with the U.S. Securities and Exchange ... of shares of its common stock. The number of ... the offering have not yet been determined. ...
Breaking Biology Technology:Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Rhythm Files Registration Statement for Proposed Initial Public Offering 2
... , , Additions to the Human Protein ... 6,100 antibodies powered by Atlas Antibodies , , ST. ... today announced the release of over 2,300 antibody additions to ... www.sigma.com/prestige ), bringing the total number of highly ...
... Austria, June 23 MIG Fonds and AFFiRiS AG are,this ... Award,competition, hosted by the industry magazine Boerse-Express and Junge,Industrie. The ... the Austrian biotechnology company as well as a euro,430 million ... Last Tuesday MIG Fonds and AFFiRiS AG were awarded ...
... June 22 Trubion Pharmaceuticals, Inc. (Nasdaq: ... of Wyeth (NYSE: WYE ), has exercised ... with Trubion to extend the research period for an ... terms of the research period extension, Wyeth,s obligations to ...
Cached Biology Technology:Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 2Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 3Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 4AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 2AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 3Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 3
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced the ... Genetics from October 18 22, 2014 in San ... the entry of students, post doctorates and scientists from ... community and to encourage the participation of young scientists ... year MARC conferred 16 awards totaling $29,600., The FASEB ...
(Date:8/28/2014)... peer groups and clinicians is critical to the ... University of Georgia research. , A qualitative study ... determined that role models for successful breastfeeding help ... , "Mothers who received that support are more ... co-author Alex Anderson, an associate professor in the ...
(Date:8/28/2014)... to Research Careers) Program has announced the travel ... Medicine,s Conference on Integrative Physiology of Exercise from ... awards are meant to promote the entry of ... into the mainstream of the basic science community ... at the American College of Sports Medicine,s Conference ...
Breaking Biology News(10 mins):Breastfeeding study shows need for effective peer counseling programs 2
... conditions leading to heart attacks and strokes are treated ... or lung, but now turn out to involve some ... This in turn provides clues to more effective therapies ... in these distinct fields to come together. The seeds ...
... DC Although Americans are becoming increasingly aware of ... A in some baby bottles and lead in some ... with personal chemical exposure and related adverse health effects, ... Journal of Health and Social Behavior . ...
... the Nov. 20 edition of Heredity could ... evolution of separate sexes, a theory that holds that ... stages are not completely understood because the majority of ... state too long ago for scientists to observe the ...
Cached Biology News:Mechanisms of cardiovascular disease and cancer give clues to new therapies 2Mechanisms of cardiovascular disease and cancer give clues to new therapies 3Pollution at home lurks unrecognized, instead attributed to large-scale environmental disasters 2Two from one: Pitt research maps out evolution of genders from hermaphroditic ancestors 2
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Request Info...
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Biology Products: